2024
588 EVEREST-1: initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH
Grierson P, Punekar S, Hazim A, Welling T, Simeone D, Kirtane K, Lim K, Morelli M, Patel S, Ulrickson M, Biachi de Castria T, Kundranda M, Vong J, Mitchell J, Langeberg W, Maus M, Bretzlaff W, Nikiforow S, Mardiros A, Maloney D, Liechty K, Locke F, Ng E, Randolph Hecht J, Go W, Molina J. 588 EVEREST-1: initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH. 2024, a670-a671. DOI: 10.1136/jitc-2024-sitc2024.0588.Peer-Reviewed Original ResearchEVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).
Molina J, Simeone D, Smith C, Welling T, Kirtane K, Grierson P, Morelli M, Hecht J, Patel S, Locke F, Weng W, Fakih M, Vong J, Liechty K, Ng E, Welch J, Maus M, Maloney D, Go W, Punekar S. EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH). Journal Of Clinical Oncology 2024, 42: tps2698-tps2698. DOI: 10.1200/jco.2024.42.16_suppl.tps2698.Peer-Reviewed Original ResearchOff-tumor toxicityT-cell therapyCAR-T cell therapyChimeric antigen receptorHLA-A*02T cellsCarcinoembryonic antigenHLA LOHNormal cellsCEA expressionSolid tumorsRecommended phase 2 doseLack of tumor-specific targetsNon-small cell lungDose-escalation portionPhase 2 doseDose-expansion phaseT-cell engagersObjective of Phase 1Tumor-specific targetingTreating solid tumorsT cell receptorOn-targetBayesian optimal interval designCheckpoint inhibitors
2023
634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)
Punekar S, Welling T, Randolph Hecht J, Molina J, Smith C, Garon E, Pia Morelli M, Fakih M, Kirtane K, Grierson P, Patel S, Lin Y, Kopetz S, Locke F, Ward J, Lozac’hmeur A, Frigault M, Nikiforow S, Weng W, Specht J, Dragovich T, Vong J, Mardiros A, Liechty K, Go W, Welch J, Ng E, Maus M, Maloney D, Simeone D. 634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH). 2023, a724-a725. DOI: 10.1136/jitc-2023-sitc2023.0634.Peer-Reviewed Original Research